| Chen, Cheng Wei |
NCT04821778: Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
|
|
| Recruiting | 3 | 2000 | RoW | Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy, Immunotherapy, 5-FU Analog based chemotherapy, Nimotuzumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy, Immunotherapy, Chemotherapy Effect | 12/25 | 12/25 | | |
TQB2450-ALTN-II-02, NCT06141226: Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 148 | RoW | TQB2450 +Anlotinib+Docetaxel, TQB2450/Anlotinib/Docetaxel, TQB2450 +Androtinib Placebo+Docetaxel, TQB2450/Anlotinib Placebo/Docetaxel | Tianjin Medical University Cancer Institute and Hospital | Non-small-cell Lung Cancer | 12/27 | 12/28 | | |
NCT06739161: Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ |
|
|
| Active, not recruiting | 2 | 120 | RoW | Sintilimab combined with chemotherapy and local treatment, Sintilimab combined with chemotherapy only | Jiangsu Cancer Institute & Hospital | Gastroesophageal Junction Adenocarcinoma | 12/27 | 12/28 | | |
RARE, NCT05941481: Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ |
|
|
| Active, not recruiting | 2 | 21 | RoW | neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab) | Jiangsu Cancer Institute & Hospital | Gastric or Gastroesophageal Junction Adenocarcinoma | 06/25 | 12/25 | | |
NCT04278287: Chemoradiotherapy in Unresectable Esophageal Cancer |
|
|
| Recruiting | 1/2 | 105 | RoW | Radiotherapy, Albumin-Bound Paclitaxel, Nab-Paclitaxel, Cisplatin, platinum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm | 12/25 | 12/26 | | |
D3S-001-100, NCT05410145: A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation |
|
|
| Recruiting | 1/2 | 392 | Europe, US, RoW | D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab | D3 Bio (Wuxi) Co., Ltd | KRAS P.G12C | 09/26 | 09/26 | | |
NCT05881317: ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study |
|
|
| Completed | N/A | 59 | RoW | ArtiAid® Plus Intra-articular Injection | Maxigen Biotech Inc. | Hyaluronic Acid | 06/22 | 11/22 | | |
| Liang, Wei |
NCT06420258: Deeper Intubation Make Effects on Cervical Esophageal ESD |
|
|
| Recruiting | 4 | 40 | RoW | Deeper endotracheal intubation | Fujian Provincial Hospital | Carcinoma in Situ of Cervical Part of Esophagus | 12/26 | 12/26 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT04694495: HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study |
|
|
| Recruiting | N/A | 10000 | RoW | 16S rRNA gene sequencing of cervical secretions, Microecology assessment of cervical secretions, Genotyping of HPV and detection of sexually transmitted diseases pathogens, Thinprep cytologic test of cervical exfoliated cells | Zhujiang Hospital, Peking University First Hospital, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, LanZhou University, Lianyungang Hospital Affiliated Bengbu Medical College, General Hospital of Ningxia Medical University, Jinan Central Hospital, Tibet Autonomous Region People's Hospital, The Affiliated Hospital Of Southwest Medical University, Anhui Provincial Hospital, The First People's Hospital of Zunyi, The Third Affiliated Hospital of Southern Medical University, First Affiliated Hospital, Sun Yat-Sen University, Zhuhai Center for Maternal and Child Health Care, First Affiliated Hospital of Guangxi Medical University, Qinghai Red Cross Hospital, Changzhi People's Hospital, Shanghai East Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Huizhou Municipal Central Hospital, Nanfang Hospital, Southern Medical University, Yuebei People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Fujian Maternity and Child Health Hospital, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Fifth Affiliated Hospital of Southern Medical University, Shandong Provincial Hospital, First Hospital of China Medical University, Gansu Provincial Hospital | Papillomavirus Infections, Uterine Cervical Neoplasms, Sexual Transmitted Disease | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
| Completed | N/A | 236 | RoW | software-delivered CBT-I, online PE | Peking University Sixth Hospital, Shenzhen Zeen Health Technology Co., Ltd., Peking University First Hospital, Sichuan Provincial People's Hospital, The Second Affiliated Hospital of AFMU, Shenzhen Kangning Hospital | Insomnia Disorder | 03/24 | 03/24 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Gao, Yunming |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
| Zhuang, Aixia |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
| Lin, Xianhe |
NCT04728516: The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients |
|
|
| Not yet recruiting | 4 | 2600 | RoW | Vonoprazan-based dual eradication therapy for two weeks, amoxicillin, Pantoprazole | Qilu Hospital of Shandong University | Acute Coronary Syndrome, Helicobacter Pylori Infection | 01/23 | 06/23 | | |
OPTIMA-6, NCT05410925: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction |
|
|
| Recruiting | 4 | 2260 | RoW | Recombinant staphylokinase, Placebo | The First Affiliated Hospital with Nanjing Medical University | ST Elevation Myocardial Infarction | 12/26 | 12/27 | | |
COOPERATION, NCT04912518: Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 250 | RoW | Dexmedetomidine (DEX), Placebo (Saline) | Harbin Medical University, Yangtze River Pharmaceutical Group Co., Ltd. | ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection | 12/24 | 12/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Zhuang, Wanchuan |
NCT05968001: Obinutuzumab in Chinese Real-world Patients With iNHL |
|
|
| Not yet recruiting | N/A | 400 | RoW | Obinutuzumab | Affiliated Hospital of Nantong University | Lymphomas Non-Hodgkin's B-Cell | 12/24 | 07/26 | | |
| Wen, Haixia |
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® |
|
|
| Not yet recruiting | 3 | 370 | RoW | Semaglutide | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Obesity | 05/26 | 10/26 | | |
